Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Seoul St. Mary's Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07240844CT.gov Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enavogliflozin (this asset) | Seoul St. Mary's Hospital | Approved | BB · 65 |
| Acoramidis | Bayer | P4 | BBB |
| Dexasone | Ascentage Pharma Group Inc. | P3 | BB |
| Empagliflozin | Columbia University | P4 | BB |
| Tafamidis | Pfizer | P4 | BB |
| Lenalidomide | Ascentage Pharma Group Inc. | P3 | BB |
| Cyclophosphamide | University of Alabama at Birmingham | P2 | BB |
| Evuzamitide | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | BB |
| Inotersen | Brigham and Women's Hospital | P3 | BB |
+26 more in the Amyloidosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enavogliflozin in Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enavogliflozin-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →